在小鼠中,Xiaoer Qixing Cha通过调节肠道微生物群和短链脂肪酸来缓解功能性便秘
Jiang He1, Huilong Lian1, Jia Wang2
1State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao, China.
概括
肖尔 (XQC) 通过恢复肠道微生物群平衡和增加有益细菌,有效治疗便秘. 这种传统的中国草药为便秘的传统治疗提供了一个有希望的替代方案.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 便秘是一种常见的胃肠道疾病,与肠道失调有关.
- 传统治疗有局限性,包括副作用和依赖性.
- 肖尔奇辛查 (XQC) 是一种用于儿科消化问题的中国草药处方,但其机制尚不清楚.
研究的目的:
- 为了研究XQC在小鼠便秘模型中的治疗效果.
- 阐明XQC对肠道微生物群和便秘的作用的机制基础.
主要方法:
- 使用高分辨率质谱学分析XQC的化学成分.
- 在洛佩拉胺诱导的便秘小鼠中评估XQC的疗效.
- 通过16S rRNA测序分析便微生物群的变化.
- 代谢分析和便微生物群移植 (FMT) 研究.
主要成果:
- 在小鼠中,XQC (141种已识别的化合物) 显著缓解了便秘症状.
- XQC恢复了肠道微生物群的平衡,增加了诸如Muribaculaceae和Bacteroides这样的有益细菌.
- FMT证实了XQC的微生物介导治疗作用,它还恢复了短链脂肪酸 (SCFA) 水平,特别是酸盐.
结论:
- XQC在缓解便秘和恢复肠道微生物平衡方面发挥了双重治疗作用.
- XQC为传统便秘疗法提供了一个可行的替代方案.
- 这项研究为基于证据的XQC在便秘管理中的应用提供了基础.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
698
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
698
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
523
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
523
Drugs for Treatment of Diarrhea-Predominant IBS
618
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
618
Drugs Affecting GI Tract Motility: Other Laxatives
1.0K
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
1.0K


